John C Watkinson1. 1. Department of ENT/Head & Neck and Thyroid Surgery, Queen Elizabeth Hospital, University of Birmingham NHS Trust, The School of Clinical and Experimental Medicine, Institute of Biomedical Research, Birmingham, UK. john.watkinson@uhb.nhs.uk
Abstract
INTRODUCTION: Thyroid disease is common, thyroid cancer is uncommon. Most goitres are investigated using blood tests, fine needle aspiration cytology together with ultrasound. Surgery usually entails either lobectomy or total thyroidectomy, and for malignancy, patients may need a neck dissection. Recently, significant advances have been made regarding mechanisms involved in both thyroid growth and function (goitrogenesis) and carcinogenesis at a molecular level. PATIENTS AND METHODS: In the study cohort, 1113 patients had benign disease and 387 malignancy. For benign disease, 716 patients had lobectomy or isthmusectomy, 44 had near-total thyroidectomy and 318 a total thyroidectomy. For malignancy, patients received initial lobectomy (180) or total thyroidectomy (152). One hundred and eleven had completion surgery. Thirty patients had extensive surgery. Thyroid growth and function was investigated using 500 human thyroid cell primary cultures obtained at surgery, as well as in three animal models. The role of pituitary tumour transforming gene (PTTG), PTTG binding factor (PBF) and sodium iodide symporter (NIS) in thyroid cell function was then evaluated. RESULTS: Temporary and permanent recurrent laryngeal nerve palsy rates were 2.4% and 0.4%. Other complications included temporary (21%) and permanent (3%) hypoparathyroidism, wound infection (1.2%), haematoma (1.2%) and poor scar (0.8%). Six patients have died. Regarding thyroid growth and function, TSH represents (either directly or indirectly) the main factor mediating thyroid follicular cell growth. For carcinogenesis, over-expression of the proto-oncogenes PTTG and PBF induces tumours in nude mice, and PTTG can induce proliferation of human thyroid cells and, in addition, both repress expression and function of NIS.
INTRODUCTION:Thyroid disease is common, thyroid cancer is uncommon. Most goitres are investigated using blood tests, fine needle aspiration cytology together with ultrasound. Surgery usually entails either lobectomy or total thyroidectomy, and for malignancy, patients may need a neck dissection. Recently, significant advances have been made regarding mechanisms involved in both thyroid growth and function (goitrogenesis) and carcinogenesis at a molecular level. PATIENTS AND METHODS: In the study cohort, 1113 patients had benign disease and 387 malignancy. For benign disease, 716 patients had lobectomy or isthmusectomy, 44 had near-total thyroidectomy and 318 a total thyroidectomy. For malignancy, patients received initial lobectomy (180) or total thyroidectomy (152). One hundred and eleven had completion surgery. Thirty patients had extensive surgery. Thyroid growth and function was investigated using 500 human thyroid cell primary cultures obtained at surgery, as well as in three animal models. The role of pituitary tumour transforming gene (PTTG), PTTG binding factor (PBF) and sodium iodide symporter (NIS) in thyroid cell function was then evaluated. RESULTS: Temporary and permanent recurrent laryngeal nerve palsy rates were 2.4% and 0.4%. Other complications included temporary (21%) and permanent (3%) hypoparathyroidism, wound infection (1.2%), haematoma (1.2%) and poor scar (0.8%). Six patients have died. Regarding thyroid growth and function, TSH represents (either directly or indirectly) the main factor mediating thyroid follicular cell growth. For carcinogenesis, over-expression of the proto-oncogenes PTTG and PBF induces tumours in nude mice, and PTTG can induce proliferation of human thyroid cells and, in addition, both repress expression and function of NIS.
Authors: James D Ramsden; Malcolm A Buchanan; Stuart Egginton; John C Watkinson; Vivien Mautner; Margaret C Eggo Journal: Endocrinology Date: 2005-04-07 Impact factor: 4.736
Authors: J D Ramsden; H C Cocks; M Shams; S Nijjar; J C Watkinson; M C Sheppard; A Ahmed; M C Eggo Journal: J Clin Endocrinol Metab Date: 2001-06 Impact factor: 5.958
Authors: S D Thompson; J A Franklyn; J C Watkinson; J M Verhaeg; M C Sheppard; M C Eggo Journal: J Clin Endocrinol Metab Date: 1998-04 Impact factor: 5.958
Authors: Dae Kim; Helen Pemberton; Anna L Stratford; Kristien Buelaert; John C Watkinson; Victor Lopes; Jayne A Franklyn; Chris J McCabe Journal: Oncogene Date: 2005-07-14 Impact factor: 9.867
Authors: K Boelaert; J Horacek; R L Holder; J C Watkinson; M C Sheppard; J A Franklyn Journal: J Clin Endocrinol Metab Date: 2006-07-25 Impact factor: 5.958
Authors: Helen C Cocks; Stuart Thompson; Frances E Turner; Ann Logan; Jayne A Franklyn; John C Watkinson; Margaret C Eggo Journal: Am J Physiol Endocrinol Metab Date: 2003-05-13 Impact factor: 4.310
Authors: Grzegorz Kaminski; Andrzej Jaroszuk; Ariadna Zybek; Krzysztof Brzozowski; Piotr Piasecki; Piotr Ziecina; Marek Ruchala Journal: Endocrine Date: 2013-10-22 Impact factor: 3.633
Authors: Suvi Renkonen; Riikka Lindén; Leif Bäck; Robert Silén; Hanna Mäenpää; Laura Tapiovaara; Katri Aro Journal: Eur Arch Otorhinolaryngol Date: 2017-09-02 Impact factor: 2.503